KBY Biotech Indexv0.0.34
Search
← Pipeline|Tixalucimab

Tixalucimab

Approved
ACH-5621
By Ache Laboratorios
Source: Trial-derived·Trials: 1
Modality
Multispecific
MOA
ALKi
Target
AHR
Pathway
Ferroptosis
MG
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
~Apr 2019
→ ~Jul 2020
NDA/BLA
~Oct 2020
→ ~Jan 2022
Approved
Apr 2022
→ Mar 2025
ApprovedCurrent
NCT05111501
866 pts·MG
2022-04→2025-03·Active
866 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2025-03-151.0y agoPh3 Readout· MG
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
Approved
Active
Catalysts
Ph3 Readout
2025-03-15 · 1.0y ago
MG
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05111501ApprovedMGActive866DAS28
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2901PfizerPhase 2AHRSOS1i
MiriosocimabPfizerPhase 1PARPALKi
MRK-7739Merck & CoPreclinicalIL-23ALKi
AZN-1715AstraZenecaPhase 3AHRFXIai
BMY-2495Bristol-Myers SquibbPhase 3KRASG12DALKi
BAY-6520BayerPhase 2AHRTROP-2 ADC
DSN-5254Daiichi SankyoPhase 1B7-H3ALKi
SovacapivasertibAmgenPhase 3WEE1ALKi
ZanuratamabGilead SciencesPhase 1/2CDK2ALKi
GIL-2445Gilead SciencesPhase 2/3PSMAALKi